http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2009148830-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-13 |
| filingDate | 2008-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2011-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2009148830-A |
| titleOfInvention | NERAMEXAN IN THE TREATMENT OF NISTAGMA |
| abstract | 1. A derivative of 1-aminoalkylcyclohexane for the treatment of nystagmus. ! 2. The use of a derivative of 1-aminoalkylcyclohexane in the manufacture of a medicament for the treatment of nystagmus. ! 3. The derivative of claim 1, wherein the 1-aminoalkylcyclohexane derivative is neramexane. ! 4. The derivative of claim 3, wherein the 1-aminoalkylcyclohexane derivative is a pharmaceutically acceptable salt of neramexane. ! 5. The derivative of claim 4, wherein the pharmaceutically acceptable salt of neramexane is neramexane mesylate. ! 6. The derivative according to any one of claims 1, 3-5, wherein the 1-aminoalkylcyclohexane derivative is administered at a dose of about 5 mg to 150 mg / day. ! 7. The derivative of claim 6, where the dose is in the range of 5 mg to 100 mg / day, or where the dose is in the range of 5 mg to 75 mg / day, or where the dose is 75 mg / day, or where the dose is 50 mg / day. ! 8. The derivative according to any one of claims 1, 3-5, wherein the 1-aminoalkylcyclohexane derivative is administered once a day, twice a day (b.i.d.) or three times a day. ! 9. The derivative of claim 8, where the derivative of 1-aminoalkylcyclohexane is administered three times a day. ! 10. The derivative of claim 9, wherein the 1-aminoalkylcyclohexane derivative is formulated in an immediate release composition or in a modified release composition. ! 11. The derivative according to any one of claims 1, 3-5, wherein the 1-aminoalkylcyclohexane derivative is combined with an additional pharmaceutical agent that has been previously found to be effective in treating nystagmus. ! 12. The derivative of claim 11, wherein the additional pharmaceutical agent is selected from baclofen, gabapentin, vigabatrin, pregabalin, memantine, 4-aminopyridine, 3,4-diaminopyridine, scopolamine and clonazepam. ! 13. Fa� |
| priorityDate | 2007-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.